Cellectis S.A.
CLLS · NASDAQ
Market closed$2.63$-0.040000 (-1.50%)After hours $2.56 · -2.66%
Key statistics
Previous close$2.67
Open$2.70
Day high$2.70
Day low$2.62
52-week high$5.48
52-week low$1.77
Market cap264.10M
Volume7.89K
Average volume32.84K
P/E ratio-3.93
Forward P/E—
EPS-0.67
Dividend yield0.00%
Market context
Why it moved
Cellectis (CLLS) edged lower amid broad market weakness driven by chip stock selloffs, geopolitical tensions with Iran, and persistent inflation concerns, overshadowing the company's recent quarterly earnings beat.
What is happening
Recent company-specific developments and publisher coverage.
MarketBeat · July 17, 2026Cellectis S.A. (NASDAQ:CLLS) Receives Average Recommendation of "Moderate Buy" from BrokeragesBarchart · July 7, 2026Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida TherapeuticsStock Titan · July 2, 2026Cellectis monthly capital update shows 100.7M shares, 105.6M votesStock Titan · June 25, 2026Cellectis shareholders back 29 motions, reject one at June 25 meetingGuruFocus · June 18, 2026Cellectis (CLLS) Receives FDA RMAT Designation for CAR-T Therapy, Shares RiseGuruFocus · June 18, 2026Cellectis (CLLS) Achieves RMAT Designation for CAR-T TherapyInvesting.com · June 10, 2026Cellectis stock rises on FDA therapy designationInvesting.com · April 14, 2026Cellectis stock rating held at outperform on allogeneic platform Mt Newswire · June 11, 2026Cellectis Says Phase 1 Lasme-cel Study Shows 100% Response Rate in B-Cell Leukemia Patients Mt Newswire · June 9, 2026Cellectis Says US FDA Granted RMAT Designation to Lasme-cel to Treat r/r B-ALL Patients Benzinga · May 28, 2026Barclays Initiates Coverage On Cellectis with Overweight Rating, Announces Price Target of $9 Benzinga · May 12, 2026Cellectis To Present Phase 1 CAR-T Data For Lasme-cel And Eti-cel At EHA 2026, Highlighting Early Safety, Response Signals And Ongoing Pivotal Programs Benzinga · May 11, 2026Cellectis Q1 Adj. EPS $(0.16) Beats $(0.27) Estimate, Sales $7.548M Miss $12.267M Estimate Benzinga · April 27, 2026Cellectis Presents New Research On TALE-Based Epigenetic Editing Approach At ASGCT Annual Meeting Benzinga · April 14, 2026Citizens Reiterates Market Outperform on Cellectis, Maintains $8 Price Target Benzinga · December 16, 2025Allogene Arbitration Victory Pressures Cellectis Shares Tuesday